ES2261040B1 - PRODUCT FOR THE TREATMENT OF ATEROGENIC LIPID DISORDERS. - Google Patents
PRODUCT FOR THE TREATMENT OF ATEROGENIC LIPID DISORDERS. Download PDFInfo
- Publication number
- ES2261040B1 ES2261040B1 ES200402762A ES200402762A ES2261040B1 ES 2261040 B1 ES2261040 B1 ES 2261040B1 ES 200402762 A ES200402762 A ES 200402762A ES 200402762 A ES200402762 A ES 200402762A ES 2261040 B1 ES2261040 B1 ES 2261040B1
- Authority
- ES
- Spain
- Prior art keywords
- nucleotides
- product
- nucleosides
- treatment
- lipid disorders
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Este producto incluye los componentes siguientes: nucleótidos y/o nucleósidos, y harina de levadura de cerveza. Dichos nucleótidos y/o nucleósidos pueden ser: Pirimidinas, tales como adenina o guanina, Purinas, tales como citosina o uracilo, o una combinación de los anteriores. Los porcentajes en peso de los componentes mencionados se encuentran comprendidos entre los valores siguientes: nucleótidos y/o nucleósidos entre un 2% y un 33% y harina de levadura de cerveza entre un 98% y un 67%.This product includes the following components: nucleotides and / or nucleosides, and beer yeast flour. Said nucleotides and / or nucleosides may be: Pyrimidines, such as adenine or guanine, Purines, such as cytosine or uracil, or a combination of the foregoing. The percentages by weight of the mentioned components are between the following values: nucleotides and / or nucleosides between 2% and 33% and beer yeast flour between 98% and 67%.
Description
Producto para el tratamiento de trastornos lipídicos aterogénicos.Product for the treatment of disorders atherogenic lipids.
La presente invención se refiere a un producto para el tratamiento de trastornos lipídicos aterogénicos, independientemente de que dichos trastornos puedan ser producidos por los efectos yatrogénicos de medicamentos, por un consumo excesivo de azúcar refinado o por cualquier otra causa.The present invention relates to a product for the treatment of atherogenic lipid disorders, regardless of whether such disorders can be produced for the yatrogenic effects of medications, for a consumption excessive refined sugar or any other cause.
Actualmente existen diferentes factores que originan trastornos lipídicos aterogénicos en el cuerpo humano y más concretamente la denominada tríada de dismetabolismo lipídico, consistente en: un aumento de los triglicéridos, un aumento de las lipoproteínas malas (VLDL) y un descenso de las lipoproteínas buenas (VHDL). Este dismetabolismo lipídico es el origen de enfermedades cardiovasculares agudas o crónicas y la mayor causa de morbi-mortalidad mundial.There are currently different factors that originate atherogenic lipid disorders in the human body and more specifically the so-called triad of lipid dysmetabolism, consisting of: an increase in triglycerides, an increase in bad lipoproteins (VLDL) and a decrease in good lipoproteins (VHDL). This lipid dysmetabolism is the origin of diseases acute or chronic cardiovascular diseases and the major cause of world morbi-mortality.
Uno de los factores que provocan este dismetabolismo lipídico es el consumo masivo de alimentos que aportan a la dieta un exceso de azúcar refinado. Este efecto negativo puede compensarse mediante el procedimiento descrito en la patente de invención 2003010090 del mismo solicitante, consistente en incorporar un porcentaje variable de nucleótidos y/o nucleósidos en aquellos alimentos que incluyen azúcares en su composición, compensado los efectos negativos del azúcar refinado.One of the factors that cause this lipid dysmetabolism is the mass consumption of foods that they contribute to the diet an excess of refined sugar. This effect negative can be compensated by the procedure described in the invention patent 2003010090 of the same applicant, consisting in incorporating a variable percentage of nucleotides and / or nucleosides in those foods that include sugars in their composition, offset the negative effects of refined sugar.
Dichos nucleótidos y/o nucleósidos pueden ser: Piramidinas (tales como adenina o guanina), Purinas (tales como citosina o uracilo) o combinaciones dedos anteriores.Said nucleotides and / or nucleosides may be: Pyramids (such as adenine or guanine), Purines (such as cytosine or uracil) or anterior finger combinations.
Otro de los factores que produce importantes dismetabolismos lipídicos es el tratamiento combinado por medio de medicamentos antiretrovirales (ARV) e inhibidores de la Proteasa (IP) que se aplica a los enfermos del V.I.H. con una eficacia demostrada. Los inhibidores de la Proteasa producen una hiperlipemia que se trata actualmente con fibratos, estatinas y ácido nicotínico o niacina.Another important factor that produces Lipid dysmetabolisms is the combined treatment by means of antiretroviral drugs (ARV) and Protease inhibitors (IP) that applies to patients with V.I.H. with an efficiency demonstrated. Protease inhibitors cause hyperlipidemia which is currently treated with fibrates, statins and nicotinic acid or niacin.
Sin embargo, este tratamiento combinado provoca unos efectos yatrogénicos secundarios, caracterizados por un aumento de los triglicéridos y de VLDL y un descenso de los VHDL, idénticos a los que ocasiona el exceso de sacarosa en la dieta, y con la diferencia de en que el caso de los enfermos de V.I.H. dichos efectos secundarios se desencadenan con una rapidez galopante, aproximadamente durante el primer año de medicación combinada.However, this combined treatment causes Yatrogenic side effects, characterized by a increased triglycerides and VLDL and a decrease in VHDL, identical to those caused by excess sucrose in the diet, and with the difference that in the case of patients with V.I.H. sayings side effects are triggered with galloping speed, approximately during the first year of combined medication.
Por tanto, el objetivo de la presente invención
es el desarrollo de un producto en forma galénica o farmacéutica,
aplicable en trastornos lipídicos producidos por los tratamientos
combinados aplicados a los enfermos del V.I.H., por un consumo
excesivo de alimentos azucarados o por cualquier otra causa que
produzca los mismos trastornos de aumento de
triglicéridos y
de VLDL y descenso de VHDL.Therefore, the objective of the present invention is the development of a product in galenic or pharmaceutical form, applicable in lipid disorders produced by the combined treatments applied to HIV sufferers, by excessive consumption of sugary foods or by any other cause that produce the same disorders increasing
triglycerides and VLDL and decrease in VHDL.
El producto objeto de esta invención es aplicable en trastornos lipídicos aterogénicos originados por diferentes causas y presenta una composición destinada a disminuir los triglicéridos y las lipoproteínas malas (VLDL) y a aumentar las lipoproteínas buenas (VHDL).The product object of this invention is applicable in atherogenic lipid disorders caused by different causes and presents a composition destined to diminish triglycerides and bad lipoproteins (VLDL) and increase Good lipoproteins (VHDL).
De acuerdo con la invención, el producto en cuestión comprende los componentes siguientes: nucleótidos y/o nucleósidos o sus mezclas y harina de levadura de cerveza.According to the invention, the product in issue comprises the following components: nucleotides and / or Nucleosides or their mixtures and brewer's yeast flour.
Los mencionados nucleótidos y/o nucleósidos pueden ser: Pirimidinas (tales como adenina, guanina), Purinas (tales como citosina, uracilo) o una combinación de las anteriores.The aforementioned nucleotides and / or nucleosides they can be: Pyrimidines (such as adenine, guanine), Purines (such as cytosine, uracil) or a combination of previous.
La incorporación de los nucleótidos y/o nucleósidos en este producto proporciona un efecto totalmente opuesto al aumento de triglicéridos y de las grasas malas y al descenso de las grasas buenas.The incorporation of nucleotides and / or nucleosides in this product provides a fully effect opposite to the increase in triglycerides and bad fats and at Decrease of good fats.
Los porcentajes en peso de dichos componentes están comprendidos dentro de los valores siguientes: nucleótidos y/o nucleósidos entre el 2% y el 33% y harina de levadura de cerveza entre el 98 y el 67%.The weight percentages of said components they fall within the following values: nucleotides and / or nucleosides between 2% and 33% and beer yeast flour between 98 and 67%.
El producto de la invención puede presentarse en forma de comprimidos, de polvo, o en cualquier otra forma que permita incluir en cada dosis los componentes mencionados y en las proporciones indicadas de cada uno de ellos.The product of the invention can be presented in tablet form, powder, or any other form that allow to include in each dose the mentioned components and in the indicated proportions of each of them.
Con la composición mencionada este producto presenta varios efectos beneficiosos, entre los cabe destacar: una acción moduladora de los nucleótidos especialmente en enfermos de V.I.H., combatir la acelerada dislipemia aterogénica por yatrogenia, un aumento directo de las defensas IgA e IgM deficitarias en los enfermos de V.I.H., así como el aumento de los anticuerpos post-vacunación y ello, tanto si se realiza con vacunas microbianas como víricas y en las que se precisa dicha potenciación y permanencia, regeneración y curación directa de la mucosa intestinal tanto la normal como la deteriorada por gérmenes, virus o enterobacterias, la obtención de grasas saludables omega- 3 y omega- 6 por elongación de los lípidos oleico y linoleico (PUFA), la obtención de un efecto beneficioso en la digestión anaeróbica del colon por la acción Pre- Biótica, logrando una reducción de la frecuencia de las diarreas, la ayuda a la recuperación ponderal con el aporte de proteínas de gran calidad y aumento del número de hematies y leucocitos.With the composition mentioned this product It has several beneficial effects, including: modulating action of nucleotides especially in patients with V.I.H., combat accelerated atherogenic dyslipidemia due to yatrogenesis, a direct increase in deficit IgA and IgM defenses in patients with V.I.H., as well as the increase in antibodies post-vaccination and this, whether done with microbial vaccines such as viral and in which such potentiation and permanence, regeneration and direct healing of the intestinal mucosa both normal and germ-damaged, virus or enterobacteria, obtaining healthy omega-3 fats and omega-6 by elongation of oleic and linoleic lipids (PUFA), obtaining a beneficial effect on anaerobic digestion of colon by Pre-Biotic action, achieving a reduction in diarrhea frequency, weight recovery aid with the contribution of high quality proteins and increasing the number of Red blood cells and leukocytes.
Asimismo, es de destacar que este producto permite seguir con su terapéutica combinada eficaz y la actual terapéutica hipo-lipemiante con estatinas y fibratos, para atenuar los efectos secundarios graves.It is also noteworthy that this product allows you to continue with your combined therapy effective and current hypo-lipemiant therapy with statins and fibrates, to mitigate serious side effects.
Una vez descrita suficientemente la naturaleza de la invención, se hace constar a los efectos oportunos que los componentes y porcentajes mencionados podrán ser modificados, siempre y cuando ello no suponga una alteración de las características esenciales de la invención que se reivindican a continuación.Once nature is sufficiently described of the invention, it is stated for the appropriate purposes that components and percentages mentioned may be modified, as long as this does not involve an alteration of the essential features of the invention claimed in continuation.
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES200402762A ES2261040B1 (en) | 2005-01-26 | 2005-01-26 | PRODUCT FOR THE TREATMENT OF ATEROGENIC LIPID DISORDERS. |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES200402762A ES2261040B1 (en) | 2005-01-26 | 2005-01-26 | PRODUCT FOR THE TREATMENT OF ATEROGENIC LIPID DISORDERS. |
Publications (2)
Publication Number | Publication Date |
---|---|
ES2261040A1 ES2261040A1 (en) | 2006-11-01 |
ES2261040B1 true ES2261040B1 (en) | 2007-11-01 |
Family
ID=37310358
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES200402762A Expired - Fee Related ES2261040B1 (en) | 2005-01-26 | 2005-01-26 | PRODUCT FOR THE TREATMENT OF ATEROGENIC LIPID DISORDERS. |
Country Status (1)
Country | Link |
---|---|
ES (1) | ES2261040B1 (en) |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1569723A4 (en) * | 2002-11-21 | 2010-02-10 | Dss Global Inc | Nucleotide based medicament and method of use for treatment of conditions in humans |
ES2219182B1 (en) * | 2003-05-12 | 2005-10-01 | Jose Luis Concellon Martinez | PROCEDURE TO COMPENSATE THE NEGATIVE EFFECT ON HEALTH OF FOODS THAT CONTAIN REFINED SUGAR. |
-
2005
- 2005-01-26 ES ES200402762A patent/ES2261040B1/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
ES2261040A1 (en) | 2006-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Seeff et al. | Herbal product use by persons enrolled in the hepatitis C Antiviral Long‐Term Treatment Against Cirrhosis (HALT‐C) Trial | |
Peters et al. | To stress or not to stress: Brain-behavior-immune interaction may weaken or promote the immune response to SARS-CoV-2 | |
Capelli et al. | Potential health benefits of Spirulina microalgae* A review of the existing literature | |
Duchan et al. | Energy drinks: a review of use and safety for athletes | |
ES2632967T3 (en) | Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of use thereof | |
Soliman et al. | Switching host metabolism as an approach to dampen SARS-CoV-2 infection | |
US11974975B2 (en) | Compositions and methods using at least one glycine or derivative thereof, at least one N-acetylcysteine or derivative thereof, and at least one nicotinamide riboside or NAD+ precursor | |
Nakamura | Application of glucosamine on human disease—Osteoarthritis | |
RU2010102237A (en) | IMPROVEMENT OF MEMORY IN PATIENTS WITH AN ESTIMATION OF 24-26 SCORES BY THE SHORT SCALE OF THE ASSESSMENT OF THE MENTAL STATUS | |
KR20160025015A (en) | Use of a composition comprising fish oil and juice for the treatment of inflammation | |
Nizam et al. | The effect of α‐tocopherol and selenium on human gingival fibroblasts and periodontal ligament fibroblasts in vitro | |
US20160095879A1 (en) | Composition for enhancing immunity | |
Gekonge et al. | Nitazoxanide inhibits HIV viral replication in monocyte-derived macrophages | |
ES2261040B1 (en) | PRODUCT FOR THE TREATMENT OF ATEROGENIC LIPID DISORDERS. | |
Singh et al. | Dawn of antioxidants and immune modulators to stop HIV-progression and boost the immune system in HIV/AIDS patients: An updated comprehensive and critical review | |
Tang et al. | The novel hepatoprotective mechanisms of silibinin-phospholipid complex against d-GalN/LPS-induced acute liver injury | |
WO2006079675A1 (en) | Product for the treatment of atherogenic lipid disorders | |
Yagi et al. | Glycative stress and anti-aging: 10. Glycative stress and liver disease. | |
WO2010147456A1 (en) | Inhibition of nfk-b mediated virus replication with specific oligosaccharides | |
Ainapurapu et al. | Trimethoprim-sulfamethoxazole induced rhabdomyolysis | |
Ram et al. | Mepacrine alleviates airway hyperresponsiveness and airway inflammation in a mouse model of asthma | |
Houston et al. | Controlling High Blood Pressure Through Nutrition, Supplements, Lifestyle and Drugs | |
RU2538083C1 (en) | Method of treating affection of vegetative parasympathetic nodes of head of herpes-virus etiology | |
Ozolinya et al. | The role of magnesium in the treatment of premenstrual syndrome | |
Dornala et al. | COVID conundrum: Possible solutions in Ayurveda |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EC2A | Search report published |
Date of ref document: 20061101 Kind code of ref document: A1 |
|
FG2A | Definitive protection |
Ref document number: 2261040B1 Country of ref document: ES |
|
FD2A | Announcement of lapse in spain |
Effective date: 20180809 |